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Suicide and suicide attempts are complex behaviors that result from the interaction of differ-
ent factors, including genetic variants that increase the predisposition to suicidal behaviors.
Copy number variations (CNVs) are deletions or duplications of a segment of DNA usually
larger than one kilobase. These structural genetic changes, although quite rare, have been
associated with genetic liability to mental disorders, such as autism, schizophrenia, and bi-
polar disorder. No genome-wide level studies have been published investigating the poten-
tial role of CNVs in suicidal behaviors. Based on single-nucleotide polymorphism array
data, we followed the Penn-CNV standards to detect CNVs in 1,608 subjects, comprising
475 suicide and suicide attempt cases and 1,133 controls. Although the initial algorithms
determined the presence of CNVs on chromosomes 6 and 12 in seven and eight cases, re-
spectively, compared with none of the controls, visual inspection of the raw data did not sup-
port this finding. Furthermore we were unable to validate these findings by CNV-specific
real-time polymerase chain reaction. Additionally, rare CNV burden analysis did not find an
association between the frequency or length of rare CNVs and suicidal behavior in our sam-
ple population. Although our findings suggest CNVs do not play an important role in the eti-
ology of suicidal behaviors, they are not inconsistent with the strong evidence from the
literature suggesting that other genetic variants account for a portion of the total phenotypic
variability in suicidal behavior.
Introduction
Suicide and related behaviors are major public health problems that account for about one mil-
lion deaths worldwide each year and impose a heavy burden on health services [1]. They are
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complex conditions, believed to result from the interaction of predisposing or distal factors,
and more immediate factors or stressors [2–4]. Genes play an important role as predisposing
factors, based on results from family, twin, and adoption studies [5]. More specifically, suicidal
behavior in relatives of suicides is more common than in relatives of healthy controls, and this
familial aggregation is only partially explained by liability to mental disorders, including major
depressive disorder (MDD) [6, 7]. Twin and adoption studies suggest that familial aggregation
of suicidal behavior is, in part, explained by genetic factors that contribute to distal predispos-
ing or protective factors that comprise the diathesis for suicidal behavior. For instance, there is
greater concordance of suicidal behavior in full siblings than in half-siblings of suicide attemp-
ters [8], and aggressive traits and mood disorders are transmitted in linkage with suicidal be-
havior [6]. Consistent with adoption data, monozygotic twins have higher concordance rates
for suicidal behavior than dizygotic twins [9], and epidemiologically representative studies sug-
gest that genes account for about 55% of the phenotypic variance in serious suicide attempts
[10]. While these studies have consistently suggested that genetic factors contribute to the pre-
disposition to suicidal behaviors, molecular studies have not yet identified specific genes. In-
deed, many candidate gene studies and several genome-wide linkage and association studies
have been conducted to date, some of which controlled for psychiatric phenotypes, and have
produced largely unreplicated results.
Copy number variations (CNVs) are deletions or duplications of a segment of DNA, usually
larger than 1 kilobase (kb). They constitute a form of genetic variation similar to other genetic
variants, such as sequence repeats and insertion/deletions. CNVs, although quite rare, have
been associated with many illnesses, including psychiatric disorders. In particular, CNVs have
been observed in de novo cases of schizophrenia [11, 12], autism spectrum disorder [13], men-
tal retardation [14], bipolar disorder [15, 16], MDD [17, 18], and other neurodevelopmental
and neuropsychiatric disorders. With respect to suicidal behaviors, only a secondary analysis
of suicide attempters was performed in a sample collected to investigate antidepressant re-
sponse in MDD [19]. Here, we report findings from a study investigating the association of
CNVs with suicidal behavior, including suicide and nonfatal suicide attempts, in a sample of
1,608 subjects, comprising 475 cases and 1,133 controls. Our study does not suggest that CNVs
associate with suicidal behavior.
Methods and Materials
Subjects
Subjects included in this study were 1,608 individuals (475 cases and 1,133 controls) selected
from a total sample of 2,382 unrelated individuals of Caucasian descent based on quality con-
trol procedures as described below. Subjects were recruited from three sites (New York, USA;
Montreal, Canada; Munich, Germany) between 1991 and 2011.
Cases consisted of those subjects who either died by suicide or attempted suicide, where a
suicide attempt was defined as a self-injurious act during which the individual had, at least,
partial intent to end his/her life. The number, method, and medical damage of past suicide at-
tempts for live subjects were recorded on the Columbia Suicide History Form. Suicidal ideation
for the USA and Canadian subjects was measured using the Scale for Suicidal Ideation [20]. Di-
agnosis of major psychiatric disorders in suicides was determined using the Structured Clinical
Interview for DSM (SCID) I by means of a validated psychological autopsy method, as previ-
ously described [21].
Controls from the Munich site were randomly selected from the general population of Mu-
nich, Germany, and were contacted by mail. Controls from the New York and Montreal sites
were solicited through advertising. The Montreal sample was composed of French Canadians,
CNVs in Suicidal Behavior
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whereas the New York sample was composed of Europeans of any origin. Controls were as-
sessed by psychiatrists or clinical psychologists and evaluated using the SCID NP version and
the SCID II. In this study, we included depressed controls and non-psychiatric controls. The
latter were free of axis I diagnoses, cluster B personality disorder, substance use disorder and
lifetime history of a suicide attempt. Depressed controls were individuals who did not have his-
tories of suicide attempts, but met criteria for MDD.
The coroner or medical examiner determined cause of death for deceased subjects. Biological
samples were obtained from the Medical Examiner’s Office in accordance with local regulations.
The Douglas Institute Research Ethics Board, the New York State Psychiatric Institute Insti-
tutional Review Board, and the Board of the Ludwig-Maximilians-University Munich, Ger-
many approved this study and written informed consent was provided by all subjects or next-
of-kin.
Quality Control (QC)
Subjects and controls were genotyped using the Illumina Omni1-Quad Beadchip. Initial QC
procedures on the genotyping data were performed using PLINK [22]. For those subjects who
passed this initial QC, single-nucleotide polymorphisms (SNPs) were filtered out of the analy-
sis if they had call rates below 95%, minor allele frequency< 0.01, or Hardy-Weinberg Equilib-
rium with p< 0.0001. Samples with ambiguous sex, genotyping call completeness<95%, and
duplicated individuals were excluded from the analyses. Five Multidimensional Scaling Analy-
sis components in PLINK and a comparison to HapMap Phase 3 populations were used to ex-
clude individuals of non-European ancestry. Logistic regression with an additive model
adjusted for the first five principal components was used to test the genotype-suicidal behavior
association. The association test was repeated separating suicide attempt and completed suicide
as outcomes. After initial QC and each of these filtering steps, 1,810 subjects remained out of
the 2,382 total sample.
CNV detection was performed using the Penn-CNV program [23] (http://www.
openbioinformatics.org/penncnv/ and http://www.openbioinformatics.org/penncnv/penncnv_
annotation.html) on the 1,810 subjects remaining after filtering, as described above. Addition-
ally, the Penn-CNV GC content correction was implemented, and subjects with greater than
50 CNVs spanning at least 30 probes were removed. After GC content correction, a total of 202
were removed, resulting in 1,608 subjects remaining for CNV analyses. Of the 1,608 subjects
(838 males and 770 females), 475 were cases with suicidal behavior (199 suicide attempters and
276 suicides) and 1,133 were controls. Additional information on the 1,608 subjects can be
found in Table 1.
Table 1. Demographic information on subjects.





Suicide Attempters 42.7 79/120
Suicide Completers 45.6 204/72
Table 1 shows the mean ages and the ratio of males (M) to females (F) for all 1608 subjects used in the
CNV analyses, separated by phenotype.
doi:10.1371/journal.pone.0128369.t001
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Data Analysis
CNV detection. Only the CNVs comprising at least 30 probes from the array were re-
tained, as reliability of CNV calls is directly related to the number of probes contained within
the CNV. Additionally, Penn-CNV findings were verified by detecting CNVs using circular bi-
nary segmentation (CBS) [24] on the same set of subjects to assess our results for consistency.
Two analyses were performed for all comparisons between cases and control: the first con-
tained all controls, regardless of the presence of MDD, while the second excluded the controls
with a history of MDD. As similar results were obtained in both analyses, the results presented
include all control samples. Power calculations can be found in Table 2.
Burden Analysis. Rare CNV segments were defined either based on their frequency or
their size. CNV segments with population frequencies of 0.1%,0.5%, or1.0%, or sizes of
100kb,200kb, or500kb were analyzed [16, 18, 25–27]. To avoid single outlier individuals
driving group effects, we considered a maximum of 20 rare CNVs per individual, as this repre-
sented the number where the frequency was close to zero. A logistic regression analysis of the
presence of a CNV (deletions and duplications combined) at each segment of the genome,
which was defined by changes in Penn-CNV-inferred copy number in at least one subject, was
performed and was adjusted for assay batch effects. Random permutations of cases and con-
trols were performed to compute two-sided, genome-wide p-values.
CNV analyses. Analyses were performed using the entire population, without differentiat-
ing phenotypes of suicidal behavior, and then by stratifying the cases based on suicidal behav-
ior, where suicides were separated from suicide attempters during analysis. Age and sex were
set as covariates and did not alter the results.
Validation
Subject selection. Cases containing the CNVs were all from the Montreal site. As such,
validations of statistically significant CNV segments were conducted in all cases having CNVs,
and in a sample of equal number of randomly selected controls from the Montreal site.
Probe selection. One TaqMan probe was selected based on genomic location (within the
boundaries of the CNV and, when applicable, within a CBS CNV call) from the Life Technolo-
gies website for chromosomes 6 and another for chromosome 12 (Hs00558050_cn and
Hs06360551_cn, respectively). RNase P (cat. #: 4403328) was used as a reference assay, as it
Table 2. Power calculations for global CNV detection.









Table 2 shows the combinations of frequencies and odds ratios that were selected based on the principle
that highly deleterious mutations, being those with high odds ratios, are more likely to be selected out of a
population. As such, their frequencies would tend to remain low. Similarly, less deleterious mutations are
likely to become more frequent in a given population.
doi:10.1371/journal.pone.0128369.t002
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only contains 2 copies. In addition, we used an individual with a confirmed deletion on chro-
mosome 3 (Taqman assay Hs03487796_cn) as a positive control for the presence of a deletion
(S1A and S1B Fig).
TaqMan Copy Number Assay. Following a standard Life Technologies protocol, quantita-
tive real-time polymerase chain reaction (qRT-PCR) was run in quadruplicate, and target probes
(FAM-MGB) were multiplexed with RNase P reference assay (VIC-TAMRA). 20ng of DNA per
subject (2.0ul) per well were mixed with 5.0ul of 2x TaqManMastermix, 0.5ul of each 20x Taq-
Man assays (target and reference), and 2.0ul of deionized H2O for a total volume of 10.0ul per
well. The plate was run on the 7900HT Real-Time PCR System using Absolute Quantification
and the 9600 emulation setting. The parameters were: 1 cycle of 10 minutes at 95°C followed by
40 cycles of 95°C for 15 seconds and 60°C for 60 seconds. The plate was then analyzed using
SDS2.4 with a manual CT threshold of 0.2. All data analyses were performed using the CopyCal-
ler software version 2.0 (Life Technologies), as per manufacturer’s instructions.
Results
In a population of 475 cases with suicidal behavior and 1,133 controls, we identified a total of
10,742 CNV calls that contained a minimum of 30 probes spanning the length of the CNV.
Fig 1 shows the distribution of CNV calls per subject (Fig 1). Within most of the CNV seg-
ments, regardless of group, few individuals had a copy number differing from two. Specifically,
of 50 CNV segments observed uniquely in cases, only 18 were present in five or more individu-
als. Similarly, of 272 CNV segments observed among controls, only 59 were present in five or
more individuals. Of the 322 CNV segments observed exclusively in either cases or controls, no
CNV was present in more than 9 subjects.
Analysis of frequency distribution of CNVs yielded no CNV segments with frequencies that
were different between nonfatal suicide attempters and controls, whereas a comparison of sui-
cides to controls identified two significantly different CNV segments (corrected p< 0.05; n = 7
for chromosome 6 and n = 8 for chromosome 12). One CNV segment comprising 166,986
bases was found on chromosome 12q12 (40,549,708–40,716,694) and contained the gene cod-
ing for leucine-rich repeat kinase 2 (LRRK2). The other CNV segment comprising 136,237
bases was found on chromosome 6p22.2 (26,150,806–26,287,043) and included a large histone
H1 gene cluster. Notably, a global comparison of all cases, including attempters and suicides
versus controls, yielded similar significant results for chromosomes 6 and 12. Neither the chro-
mosome 6 nor the chromosome 12 CNV segment was present in any of the 1,133 controls ana-
lyzed in this study. Neither of the two CNV segments has been previously reported in studies
investigating psychiatric phenotypes.
As literature in neuropsychiatric disorders suggests that rare CNVs may be causative for
complex diseases [25–27], we performed a rare CNV burden analysis to determine if there
were more rare CNV segments in individuals with suicidal behavior as compared to controls.
When performing the burden analysis, we conducted logistic regressions of phenotype on the
adjusted number of CNVs. We found the increase in suicide risk with each additional rare
CNV was positive, but non-significant (p> 0.05). Results for analyses using varying frequen-
cies and sizes of CNVs can be found in Table 3. When comparing the mean number of rare
CNVs between cases and controls, the former had an average of 1.2 times the number of CNVs
of the controls (two-sided p> 0.05).
For validation, we used qRT-PCR TaqMan copy number assays, testing one genomic region
that was common among all individuals carrying the 12q12 CNV segment, and, similarly, a ge-
nomic region common among all individuals carrying the 6q22.2 CNV segment. We were un-
able to validate the presence of a CNV on either chromosome (Fig 2). The qRT-PCR analysis
CNVs in Suicidal Behavior
PLOS ONE | DOI:10.1371/journal.pone.0128369 May 26, 2015 5 / 11
determined with greater than 99% confidence that all subjects, cases and controls alike, con-
tained two copies of the region of interest.
Discussion
CNVs represent deletions or duplications of a segment of DNA, usually larger than 1 kb, and have
previously been linked to neurodevelopmental disorders, such as autism and schizophrenia. Our
study is the first genome-wide CNV analysis where suicide behavior was the primary criterion for
recruitment. A previous CNV study was a secondary analysis of suicidal behavior in subjects with
major depressive disorder recruited for a large trial of antidepressant treatment [19]. This study
found several loci that did not reach genome-wide significance. An additional study was a case re-
port generated from a study of bipolar patients and described a CNV in the 5-HTR1A gene in a
Fig 1. Distribution of CNV calls per subject. The figure represents a histogram with the frequency of CNV calls, with at least 30 probes, per subject.
doi:10.1371/journal.pone.0128369.g001
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single individual with history of suicide attempts [28]. Finally, a third study was of suicides and fo-
cused on CNVs in discrete genomic loci coding for CYP2D6 and CYP2C19 [29].
In our sample, we did not find evidence for the effects of CNVs previously reported in stud-
ies investigating patients with schizophrenia, developmental disorders, or mood disorders [30],
nor for effects of CNVs reported in the studies of suicidal behavior discussed above [19, 28,
29]. Our initial genome-wide analysis identified one CNV segment on chromosome 12q12 and
one CNV segment on chromosome 6p22.2, respectively in eight and seven cases, and no con-
trols. The CNV segment on chromosome 12q12 contained the LRRK2 gene. Point mutations
in LRRK2 are considered the most significant contributor to the pathogenesis of Parkinson’s
disease, although the exact molecular mechanism has yet to be established [31–33]. Additional-
ly, a specific variant of LRRK2 may have a protective role in patients with sporadic Alzheimer’s
disease [34]. Regardless, LRRK2 may be of interest for suicidal behaviors as this gene is thought
to increase the transcriptional activity of genes, either by inhibiting the action of Argonaute in
the microRNA activity pathway [35] or by targeting ribosomal proteins [36]. Therefore, it may
regulate the activity of genes involved in the neurobiology of suicidal behavior.
The CNV segment on chromosome 6p22.2 comprised a histone H1 gene cluster. Histones
in the H1 family play a role in both the core histone complex, known as the nucleosome, and
linker histones. Importantly, histones are susceptible to post-translational modifications, with
potential effects on their ability to package the DNA. Changes in the interactions between his-
tone complexes and DNA strands ultimately lead to changes in the expression of the genes en-
coded by the given segment of DNA, without altering the underlying DNA sequence. This type
of epigenetic process has been a key focus of recent studies aiming to decipher the neurobiology
of psychiatric disorders. Interestingly, microRNAs are also considered key to the role of epige-
netics on disease pathogenesis. Given known effects of LRRK2 on Argonaute, one could hy-
pothesize that an interaction between histone-related epigenetic alterations and
LRRK2-induced microRNA dysfunctions may be related to the etiology of suicidal behavior.
Although our CNV investigation provided two interesting results, we were unable to con-
firm the presence of a CNV at these loci by an independent, low-throughput method
(qRT-PCR). Array-based methodologies are less reliable, whereas qPCR-based assays are more
sensitive and accurate [37, 38], and this may explain the lack of validation. Similarly, our inabil-
ity to replicate previous findings in MDD [17], treatment-resistant MDD [18], or suicide [19,
29] is possibly a result of the large and heterogeneous sample set we investigated or of differ-
ences in the severity of the phenotypes investigated.
Table 3. CNV burden analyses usingmultiple parameters.
Total p valuea ORb Power
Frequency
0.1% 1,363 0.18 1.07 0.53
 0.5% 3,134 1.0 1.01 0.02
 1.0% 3,987 1.0 1.02 0.13
Size
 100kb 3,289 1.0 1.03 0.10
 200kb 1,251 1.0 1.09 0.19
 500kb 192 0.91 0.746 0.20
Table 3 shows the effect of CNV burden based on the frequencies or sizes of the CNVs.
ap values are Bonferroni corrected
bOR: Odds Ratios for each additional CNV
doi:10.1371/journal.pone.0128369.t003
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CNVs have been more definitively associated with neurodevelopmental conditions, particu-
larly autism and schizophrenia, and arguably less so with mood disorders, which is the most
frequent psychopathology associated with suicidal behavior. Both the previous genome-wide
CNV study investigating suicidal behavior [19] and our study failed to identify significant evi-
dence of increased burden of rare CNVs or mean number of CNVs. Thus, if CNVs are
Fig 2. Validation of CNV call from SNP-array data does not confirm the presence of a CNV on Chromosomes 6 and 12. Seven (chromosome 6) or
eight (chromosome 12) cases (grey) and eight controls (black) were probed with a TaqMan Copy Number Assay to determine the presence of a CNV. This
probe was normalized to the RNase P endogenous control. Data shown represents the calculated copy number ± the copy number range, as determined by
CopyCaller 2.0.
doi:10.1371/journal.pone.0128369.g002
CNVs in Suicidal Behavior
PLOS ONE | DOI:10.1371/journal.pone.0128369 May 26, 2015 8 / 11
etiologically related to suicidal behavior, they are likely to explain only a small fraction of the
total genetic variability.
In summary, the present study conducted a CNV analysis in a large sample of individuals
with suicidal behavior and did not uncover a validated CNV associated with this phenotype.
Since both this study and previous ones suggest CNVs in suicidal behavior are rare, future re-
search should use methods that increase the likelihood of detecting these rare variants. Al-
though detecting CNVs from next-generation sequencing data is currently challenging [39],
sequencing studies are quickly becoming more feasible and affordable, and should provide the
necessary sensitivity to determine the role of CNVs in suicidal behavior.
Supporting Information
S1 Fig. Positive control for CNV validation confirms validity of genome-wide assays and
validation technique. A) Raw data from genome-wide CNV analysis shows a deletion on chro-
mosome 3. B) TaqMan Copy Number Assay confirms the presence of a deletion on chromo-
some 3 in an individual subject compared to 8 control subjects. This probe was normalized to
the RNase P endogenous control. Data shown represents the calculated copy number ± the
copy number range, as determined by CopyCaller 2.0
(PDF)
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